| 췌도부전당뇨병에 대한 입장 성명서 |
|
김지윤1, 진상만1, 김규리1, 김수경2, 김원준3, 문선준4, 유지희5, 이다영6, 이승은7, 전지은8, 김재현1, 대한당뇨병학회 췌도부전당뇨병 TFT |
1성균관대학교 의과대학 삼성서울병원 내분비대사내과
2경상대학교 의과대학 경상국립대학교병원 내분비내과
3울산대학교 의과대학 강릉아산병원 내분비내과
4성균관대학교 의과대학 강북삼성병원 내분비내과
5중앙대학교 의과대학 중앙대학교광명병원 내분비내과
6고려대학교 의과대학 고려대학교안산병원 내분비내과
7울산대학교 의과대학 울산대학교병원 내분비내과
8경희대학교 의과대학 강동경희대병원 내분비대사내과 |
| A Position Statement on Diabetes with β-Cell Failure |
|
Ji Yoon Kim1, Sang-Man Jin1, Gyuri Kim1, Soo Kyoung Kim2, Won Jun Kim3, Sun Joon Moon4, Jee Hee Yoo5, Da Young Lee6, Seung-Eun Lee7, Ji Eun Jun8, Jae Hyeon Kim1, Korean Diabetes Association Task Force Team for Diabetes with β-Cell Failure |
1Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea
3Department of Endocrinology and Metabolism, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea
4Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
5Division of Endocrinology and Metabolism, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea
6Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
7Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
8Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea |
Correspondence:
Jae Hyeon Kim,
Email: jaehyeon@skku.edu
|
|
Received: 31 July 2024 • Accepted: 22 August 2024 |
| Abstract |
|
Diabetes mellitus is a heterogeneous disease that encompasses a wide range of conditions, from mild cases to severe conditions where survival depends on insulin therapy. The Korean Diabetes Association Task Force Team for Diabetes with β-Cell Failure has established the term to classify severe refractory disease with β-cell failure. Individuals with β-cell failure are at high risk of diabetes-related complications. We propose that diabetes with β-cell failure can be diagnosed when individuals treated with multiple daily insulin injections or insulin pumps meet at least one of the following criteria: fasting C-peptide ≤ 0.6 ng/mL, non-fasting C-peptide ≤ 1.8 ng/mL, 24-hour urine C-peptide < 30 μg/day, or spot urine C-peptide/creatinine ratio ≤ 0.6 nmol/mmol. Among cases of diabetes with β-cell failure, β-cell failure with absolute insulin deficiency can be diagnosed when at least one of the following criteria is met: fasting C-peptide < 0.24 ng/mL, non-fasting C-peptide < 0.6 ng/mL, or spot urine C-peptide/ creatinine ratio < 0.2 nmol/mmol. Multiple daily insulin injections with long-acting insulin analogs and rapid-acting insulin analogs or insulin pumps are required for treatment of diabetes with β-cell failure. Continuous glucose monitoring and an automated insulin delivery system, sensor-augmented pump, or smart insulin pen, along with structured education, are necessary. We call for improvements in the relevant systems to ensure that such treatments can be provided. |
| Key Words:
Continuous glucose monitoring, Diabetes mellitus, Insulin-secreting cells, Islets of Langerhans, Pancreas, artificial |
|
PDF Links
Full text via DOI
Download Citation
